A randomized, open-label, multi-center phase II study to compare bevacizumab plus sorafenib versus sorafenib for the third-line treatment of patients with metastatic renal cell carcinoma (NCT02330783) | |
Guo, Jun; Sheng, Xi Nan; Chi, Zhihong; Cui, Chuanliang; Si, Lu; Li, Si Ming; Mao, Li Li; Lian, Bin; Tang, Bixia; Yan, Xieqiao | |
2015 | |
卷号 | 33 |
期号 | 15 |
会议录 | JOURNAL OF CLINICAL ONCOLOGY |
语种 | 英语 |
URL标识 | 查看原文 |
ISSN号 | 0732-183X |
内容类型 | 会议论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/4866864 |
专题 | 复旦大学上海医学院 |
推荐引用方式 GB/T 7714 | Guo, Jun,Sheng, Xi Nan,Chi, Zhihong,et al. A randomized, open-label, multi-center phase II study to compare bevacizumab plus sorafenib versus sorafenib for the third-line treatment of patients with metastatic renal cell carcinoma (NCT02330783)[C]. 见:. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论